ID: ALA5073757

Max Phase: Preclinical

Molecular Formula: C47H61N7O6S

Molecular Weight: 852.11

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCCCCC(=O)Nc2ccc(C(=O)Nc3ccccc3N)cc2)C(C)(C)C)cc1

Standard InChI:  InChI=1S/C47H61N7O6S/c1-31-42(61-30-50-31)33-21-19-32(20-22-33)28-49-45(59)39-27-36(55)29-54(39)46(60)43(47(2,3)4)53-41(57)18-12-10-8-6-5-7-9-11-17-40(56)51-35-25-23-34(24-26-35)44(58)52-38-16-14-13-15-37(38)48/h13-16,19-26,30,36,39,43,55H,5-12,17-18,27-29,48H2,1-4H3,(H,49,59)(H,51,56)(H,52,58)(H,53,57)/t36-,39+,43-/m1/s1

Standard InChI Key:  AQIQXAQNDASVRZ-IPQHXDNUSA-N

Associated Targets(Human)

VHL/Histone deacetylase 2 81 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 1 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 3 77 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HCT-116 91556 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 852.11Molecular Weight (Monoisotopic): 851.4404AlogP: 7.60#Rotatable Bonds: 20
Polar Surface Area: 195.85Molecular Species: NEUTRALHBA: 9HBD: 6
#RO5 Violations: 3HBA (Lipinski): 13HBD (Lipinski): 7#RO5 Violations (Lipinski): 4
CX Acidic pKa: 12.67CX Basic pKa: 3.24CX LogP: 5.75CX LogD: 5.75
Aromatic Rings: 4Heavy Atoms: 61QED Weighted: 0.04Np Likeness Score: -0.68

References

1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT..  (2022)  Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.,  65  (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179]
2. Cross JM, Coulson ME, Smalley JP, Pytel WA, Ismail O, Trory JS, Cowley SM, Hodgkinson JT..  (2022)  A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.,  13  (12.0): [PMID:36545434] [10.1039/d2md00199c]
3. He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, Xie T, Ye XY..  (2022)  Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).,  227  [PMID:34775332] [10.1016/j.ejmech.2021.113946]

Source